词条 | Loratadine |
释义 |
| Verifiedfields = changed | verifiedrevid = 408580634 | drug_name = | IUPAC_name = Ethyl 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidinecarboxylate | image = Loratadine.svg | image2 = Loratadine - 3d, portrait orientation.png | tradename = Claritin, Claratyne, others | Drugs.com = {{drugs.com|monograph|loratadine}} | MedlinePlus = a697038 | pregnancy_AU = B1 | pregnancy_US = B | legal_UK = GSL | legal_US = OTC | legal_CA = OTC | routes_of_administration = by mouth | bioavailability = almost 100% | protein_bound = 97–99% | metabolism = liver (CYP2D6- and 3A4-mediated) | elimination_half-life = 8 hours, active metabolite desloratadine 27 hours | excretion = 40% as conjugated metabolites into urine Similar amount into the feces | IUPHAR_ligand = 7216 | CAS_number_Ref = {{cascite|correct|??}} | CAS_number = 79794-75-5 | ATC_prefix = R06 | ATC_suffix = AX13 | PubChem = 3957 | DrugBank_Ref = {{drugbankcite|changed|drugbank}} | DrugBank = DB00455 | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID = 3820 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = 7AJO3BO7QN | KEGG_Ref = {{keggcite|correct|kegg}} | KEGG = D00364 | ChEMBL_Ref = {{ebicite|correct|EBI}} | ChEMBL = 998 | C=22 | H=23 | Cl=1 | N=2 | O=2 | molecular_weight = 382.88 g/mol | smiles = O=C(OCC)N4CC/C(=C2/c1ccc(Cl)cc1CCc3cccnc23)CC4 | StdInChI_Ref = {{stdinchicite|correct|chemspider}} | StdInChI = 1S/C22H23ClN2O2/c1-2-27-22(26)25-12-9-15(10-13-25)20-19-8-7-18(23)14-17(19)6-5-16-4-3-11-24-21(16)20/h3-4,7-8,11,14H,2,5-6,9-10,12-13H2,1H3 | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | StdInChIKey = JCCNYMKQOSZNPW-UHFFFAOYSA-N }}Loratadine, sold under the brand name Claritin among others, is a medication used to treat allergies.[1] This includes allergic rhinitis (hay fever) and hives.[1] It is also available in combination with pseudoephedrine, a decongestant, known as loratadine/pseudoephedrine.[1] It is taken by mouth.[1] Common side effects include sleepiness, dry mouth, and headache.[1] Serious side effects are rare and include allergic reactions, seizures, and liver problems.[6] Use during pregnancy appears to be safe but has not been well studied.[2] It is not recommended in children less than two years old.[3] It is in the second-generation antihistamine family of medication.[1] Loratadine was patented in 1980 and came to market in 1988.[4] It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.[5] Loratadine is available as a generic medication.[1] The wholesale cost in the developing world is about US$0.01 to 0.06 per dose as of 2015.[6] In the United States, it is available over the counter.[1] Medical usesLoratadine is indicated for the symptomatic relief of allergy such as hay fever (allergic rhinitis), urticaria (hives), chronic idiopathic urticaria,[7] and other skin allergies.[8] For allergic rhinitis, loratadine is effective for both nasal and eye symptoms - sneezing, runny nose, and itchy or burning eyes. Similarly to cetirizine, loratadine attenuates the itching associated with Kimura's disease.[9] FormsThe drug is available in many different forms, including tablets, oral suspension, and syrup,[8] and in combination with pseudoephedrine.[10] Also available are quick-dissolving tablets, which are marketed as being faster to get into one's circulatory system, but require special handling to avoid degrading in the package. ContraindicationsPatients with severe hepatic (liver) disorders may need to start with a lower dose. No dose adaptation is necessary for elderly or renally (kidney) impaired patients.[8][11] Loratadine is usually compatible with breast feeding (classified category L-2 by the American Academy of Pediatrics).[12] In the U.S., it is classified as category B in pregnancy, meaning animal reproduction studies have failed to demonstrate a risk to the fetus, but no adequate and well-controlled studies in pregnant women have been conducted.[13] Adverse effectsAs a "non-sedating" antihistamine, loratadine causes less (but still significant, in some cases) sedation and psychomotor retardation than the older antihistamines because it penetrates the blood/brain barrier to a smaller extent.[14] Other possible side effects include headache and antimuscarinic effects such as urinary retention, dry mouth, blurred vision, and gastrointestinal problems.[8][11] InteractionsSubstances that act as inhibitors of the CYP3A4 enzyme such as ketoconazole, erythromycin, cimetidine, and furanocoumarin derivatives (found in grapefruit) lead to increased plasma levels of loratadine — that is, more of the drug was present in the bloodstream than typical for a dose. This had clinically significant effects in controlled trials of higher-than-usual doses of loratadine (20 mg).[15] Antihistamines should be discontinued about 48 hr prior to skin allergy tests, since these drugs may prevent or diminish otherwise-positive reactions to dermal activity indicators. PharmacologyPharmacodynamicsLoratadine is a tricyclic antihistamine, which acts as a selective inverse agonist of peripheral histamine H1 receptors.[11][16] The potency of second generation histamine antagonists is (from strongest to weakest) desloratadine (Ki 0.4 nM) > levoceterizine (Ki 3 nM) > cetirizine (Ki 6 nM) > fexofenadine (Ki 10 nM) > terfenadine > loratadine. However, the onset of action varies significantly and clinical efficacy is not always directly related to only the H1 receptor potency.[16]{{Verify source|date=June 2017}} PharmacokineticsLoratadine is given orally, is well absorbed from the gastrointestinal tract, and has rapid first-pass hepatic metabolism; it is metabolized by isoenzymes of the cytochrome P450 system, including CYP3A4, CYP2D6, and, to a lesser extent, several others.[17][18] Loratadine is almost totally (97–99%) bound to plasma proteins. Its metabolite desloratadine, which is largely responsible for the antihistaminergic effects, binds to plasma proteins by 73–76%.[8] Loratadine's peak effect occurs after 1-2 hours, and its biological half life is on average 8 hours (range 3 to 20 hours) with desloratadine's half-life being 27 hours (range 9 to 92 hours), accounting for its long-lasting effect.[19] About 40% is excreted as conjugated metabolites into the urine, and a similar amount is excreted into the feces. Traces of unmetabolised loratadine can be found in the urine.[8] In structure, it is closely related to tricyclic antidepressants, such as imipramine, and is distantly related to the atypical antipsychotic quetiapine.[20] HistorySchering-Plough developed loratadine as part of a quest for a potential blockbuster drug: a nonsedating antihistamine. However, by the time Schering submitted the drug to the U.S. Food and Drug Administration (FDA) for approval, the agency had already approved a competitor's nonsedating antihistamine, terfenadine (trade name Seldane), and, therefore, put loratadine on a lower priority.[21]Loratadine was approved by the FDA in 1993.[21] The drug continued to be available only by prescription in the U.S. until it went off patent in 2002.[22] It was then subsequently approved for over-the-counter sales. Once it became an unpatented over-the-counter drug, the price dropped significantly. Schering also developed desloratadine (Clarinex/Aerius), which is an active metabolite of loratadine. Society and cultureOver-the-counter regulationIn 1998, in an unprecedented action, the American insurance company Anthem petitioned the FDA to allow loratadine and two other antihistamines to be made available over the counter (OTC) while it was still under patent; the FDA granted the request, which was not binding on manufacturers.[23] In the US, Schering-Plough made loratadine available OTC in 2002.[23] As of 2015 loratadine was available in many countries OTC.[24] BrandsAs of 2017, loratadine was available under many brand names and dosage forms worldwide, including several combination drug formulations with pseudoephedrine, paracetamol, betamethasone, ambroxol, salbutamol, phenylephrine, and dexamethasone.[25] {{collapse top|Listing of brands}}As of 2017 brands included: Actalor, Actidin, Aerotina, Alaspan, Alavert, Albatrina, Alerdina, Alerfast, Alergan, Alergiano, Alergiatadina, Alergin Ariston, Alergipan, Alergit, Alergitrat L, Aleric Lora, Alermuc, Alernitis, Alerpriv, Alertadin, Alertine, Aleze, Algac, Algecare, Algistop, Alledryl, Aller-Tab, Allerfre, Allerget, Allergex Non Drowsy, Allergyx, Allerhis, Allernon, Allerta, Allertyn, Allohex, Allor, Allorat, Alloris, Alor, Analor, Anhissen, Anti-Sneeze, Antial, Antil, Antimin, Ao Hui Feng, Ao Mi Xin, Ao Shu, Ardin, Atinac, Avotyne, Axcel Loratadine, Bai Wei Le, Bang Nuo, Bedix, Belodin, Benadryl, Besumin, Bi Sai Ning, Bi Yan Tong, Biliranin, Biloina, Biolorat, Bollinol, Boots Hayfever Relief, Boots Hooikoortstabletten, Boots Once-a-Day Allergy Relief, Carin, Carinose, Chang Ke, Civeran, Clara, Claratyne, Clarid, Clarihis, Clarihist, Clarilerg, Clarinese, Claritin, Claritine, Clarityne, Clarityne SP, Clarotadine, Clatatin, Clatine, Clear-Atadine, Clear-Atadine Children's, Clistin, Contral, Cronitin, Da Sheng Rui Li, Dao Min Qi, Dayhist, Debimin, Desa, Devedryl, Dexitis, Dimegan, Dimens, Dimetapp Children's ND Non-Drowsy Allergy, Doliallérgie Loratadine, Effectine, Eladin, Elo, Emilora, Encilor, Eradex, Erolin, Ezede, Fei Ge Man, Finska, Flonidan, Flonidan Control, Florgan, Folerin, Frenaler, Fristamin, Fu Lai Xi, Fucole Minlife, Genadine, Glodin, Gradine, Halodin, Helporigin, Hisplex, Histaclar, Histafax, Histalor, Horestyl, Hua Chang, Hysticlar, Igir, Immunix, Immunex, Inclarin, Inversyn, Jin Su Rui, Jing Wei, Ke Mi, Klarihist, Klinset, Klodin, Kui Yin, Lallergy, Larotin, Latoren, Laura, LD, Lei Ning, Lesidas, Liberec, Lisaler, Logadine, Logista, Lohist, Lolergi, Lolergy, Lomidine, Lomilan, Loptame, Lora, Lora-Lich, Lora-Mepha Allergie, Loracare, Loracil, Loraclear, Loradad, Loraderm, Loradin, Loradine, Lorado Pollen, Loradon, Lorafix, Lorahexal, Lorahist, Lorakids, Loralab-D, Loralerg, Loralivio, Loramax, Loramin, Loramine, Loran, Lorange, Loranil, Lorano, Loranox, Lorantis, LoraPaed, Lorastad, Lorastamin, Lorastine, Lorastyne, Lorat, Loratab, Loratadim, Loratadin, Loratadina, Loratadine, Loratadinum, Loratadyna, Loratan, Loratin, Loraton, Loratrim, Loratyne, Lorchimin, Lordamin, Lordinex, Loremex, Loremix, Lorfast, Lorid, Loridin, Lorihis, Lorimox, Lorin, Lorine, Loristal, Lorita, Loritex, Loritin, Lorly, Lormeg, Lorsedin, Lortadine, Losta, Lostop, Lotadin, Lotadine, Lotarin, Lotin, Megalorat, Mildin, Min Li Ke, Minlife, Mintapp, Mosedin, Mudantil L, Nasaler, Neoday, Niltro, Non-Drowsy Allergy Relief, Nosedin, Noseling, Novacloxab, NT-Alergi, Nufalora, Nularef, Numark Allergy, Omega, Oradin, Oradine, Oramine, Orin, Orinil, Pollentyme, Pressing, Pretin, Primorix, Profadine, Pulmosan Aller, Pylor, Rahistin, Ralinet, Ramitin, Refenax, Restamine, Rhinigine, Rihest, Rinalor, Rinconad, Rinityn, Rinolan, Riprazo, Rityne, Roletra, Rotadin, Rui Fu, Run Lai, Rupton, Sensibit, She Tai, Shi Nuo Min, Shi Tai Shu, Shu Rui, Shun Ta Xin, Silora, Sinaler, Sohotin, Soneryl, Sunadine, Symphoral, Tabcin, Tai Ming Ke, Ticevis, Tidilor, Tinnic, Tirlor, Toral, Triaminic, Tricel, Tuulix, Urtilar, Utel, Vagran, Winatin, Xanidine, Xepalodin, Xian Ning, Xin Da Yue, Xing Yuan Jia, XSM, Xue Fei, Yi Fei, Yi Shu Chang, Yibang, Zhengshu, Zhi Min, Zifar, Zoratadine, and Zylohist.[25] As of 2017, in a combination drug with pseudoephedrine, it was available under the brands: Airet, Alavert D-12, Aldisa SR, Alerfast D, Alergical LP, Alergin Plus Ariston, Alerpriv D, Alledryl-D, Allerpid, Aseptobron Descongestivo, Bai Wei Qing, Benadryl 24 D, Ciprocort D, Claridex, Claridon, Clarinase, Clarinase Repetab, Claritine Active, Claritin Allergy + Sinus, Clarityne, Clarityne D, Clarityne-D, Clear-Atadine, Coderin, Cronase, De-Cold, Decidex Plus, Decongess I, Defonase, Demazin NS, Dimegan-D, Effectine D, Ephedrol, Fedyclar, Finska-LP, Frenaler-D, Hui Fei Shun, Ke Shuai, Claritin-D, Larotin D, Lertamine, Lohist-Extra, Lora Plus, Loralerg D, Loranil-D, Loratin D, Loratin Plus, Lordinex D, Loremix D, Lorexin-D, Lorfast-D, Loridin-D, Lorinase, Minlife -P, Mosedin plus sr, Narine Repetabs, Nasaler Plus, Nularef-D, Oradin Plus, Pretin-D, Primorix-D, Rhinos SR, QiKe, Rinomex, Sinaler D, Sudamin, Sudolor, Tricel-D, Zhuang Qi, Zoman-D, and Zoratadine-P.[25] As of 2017, in a combination drug with paracetamol, it was available as Sensibit D and in combination with paracetamol and pseudoephedrine, it was available as: Atshi, Clariflu, and Trimed Flu.[25] As of 2017, in a combination drug with betamethasone, it was available as Celestamincort, Celestamine NF, Celestamine NS, Celestamine* L, Ciprocort L, Claricort, Clarityne cort, Corticas L, Cortistamin-L, Histafax Compuesto, Histamino Corteroid L, Labsalerg-B, Lisaler Beta, and Sinaler B, and in combination with betamethadol with available as Nularef Cort.[25] As of 2017, in a combination drug with ambroxol, it was available as Aliviatos, Ambroclar, Antitusivo L Labsa, Bronar, Broncovital, Broquixol, Clarixol, Ideobron, Lorabrox, Lorfast-AM, Sensibit XP, and Toraxan, and in a combination drug with ambroxol and salbutamol as Sibilex.[25] As of 2017, in a combination drug with phenylephrine, it was available as Bramin-Flu, Clarityne D, Clarityne Plus, Clarityne-D, Histafax D, Brafelix, Loramine R, Loraped, Maxiclear Cold & Nasal, Maxiclear Hayfever & Sinus Relief, and Rinavent, and in combination with phenylephrine and paracetamol it was available as Sensibit D NF.[25] As of 2017, in a combination drug with dexamethasone it was available as Alerfast Forte and Frenaler Forte.[25] {{collapse bottom}}MarketingThe marketing of the Claritin brand is important in the history of direct-to-consumer advertising of drugs.[51][52] The first television commercial for a drug was aired in the US in 1983 by Boots, and sparked controversy. The FDA responded with strong regulation requiring disclosure of side effects and other information. These rules made pharmaceutical manufacturers balk at spending money on ads that had to highlight negative aspects.[26] In the mid-1990s, the marketing team for Claritin at Schering-Plough found a way around these rules. They created brand awareness commercials that never actually said what the drug was for, but instead showed sunny images, and the voiceover said things like "At last, a clear day is here" and "It's time for Claritin" and repeatedly told viewers to "ask your doctor" about Claritin.[26][52] The first ads succeeded in making people aware of the brand and increased prescriptions, which led Schering-Plough and others to aggressively pursue the advertising strategy.[27] This trend, along with advice from its attorneys that it could not win a First Amendment case on the issue, led the FDA to issue new rules for TV commercials in 1997.[26] Instead of including the "brief summary" that took up a full page in magazine ads and would take too long to explain in a TV commercial, drug makers were allowed to refer viewers to print ads, 1-800 numbers, or websites, and urge people to talk to their doctor if they wanted additional information.[26][28] Schering-Plough invested $322 million in Claritin direct-to-consumer advertising in 1998 and 1999, far more than any other brand.[29] Overall, spending on direct-to-consumer advertising by the pharmaceutical industry rose from $360 million in 1995 to $1.3 billion in 1998, and by 2006, was $5 billion.[26] See also
References1. ^1 2 3 4 5 6 7 {{cite web|title=Loratadine|url=https://www.drugs.com/monograph/loratadine.html|publisher=The American Society of Health-System Pharmacists|accessdate=8 December 2016|deadurl=no|archiveurl=https://web.archive.org/web/20161221001703/https://www.drugs.com/monograph/loratadine.html|archivedate=21 December 2016|df=}} 2. ^{{cite web|title=Loratadine Use During Pregnancy {{!}} Drugs.com|url=https://www.drugs.com/pregnancy/loratadine.html|website=www.drugs.com|accessdate=13 December 2016|deadurl=no|archiveurl=https://web.archive.org/web/20161221001209/https://www.drugs.com/pregnancy/loratadine.html|archivedate=21 December 2016|df=}} 3. ^1 {{cite web|title=Clarityn Allergy 10mg Tablets (P) - Summary of Product Characteristics (SPC) - (eMC)|url=https://www.medicines.org.uk/emc/medicine/29550|date=7 October 2015|website=www.medicines.org.uk|accessdate=13 December 2016|deadurl=no|archiveurl=https://web.archive.org/web/20161220173725/https://www.medicines.org.uk/emc/medicine/29550|archivedate=20 December 2016|df=}} 4. ^{{cite book |last1=Fischer |first1=Jnos |last2=Ganellin |first2=C. Robin |title=Analogue-based Drug Discovery |date=2006 |publisher=John Wiley & Sons |isbn=9783527607495 |page=549 |url=https://books.google.ca/books?id=FjKfqkaKkAAC&pg=PA549 |language=en}} 5. ^{{cite web|title=WHO Model List of Essential Medicines (19th List)|url=http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1|work=World Health Organization|accessdate=8 December 2016|date=April 2015|deadurl=no|archiveurl=https://web.archive.org/web/20161213052708/http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1|archivedate=13 December 2016|df=}} 6. ^{{cite web|title=Loratadine|url=http://mshpriceguide.org/en/single-drug-information/?DMFId=925&searchYear=2015|website=International Drug Price Indicator Guide|accessdate=1 June 2018}} 7. ^{{cite journal | pmid = 17229605| year = 2006| author1 = Pons-Guiraud| first1 = A| title = Emedastine difumarate versus loratadine in chronic idiopathic urticaria: A randomized, double-blind, controlled European multicentre clinical trial| journal = European Journal of Dermatology : EJD| volume = 16| issue = 6| pages = 649–54| last2 = Nekam| first2 = K| last3 = Lahovsky| first3 = J| last4 = Costa| first4 = A| last5 = Piacentini| first5 = A}} 8. ^1 2 3 4 5 {{cite book|title=Austria-Codex|editor=Jasek, W|publisher=Österreichischer Apothekerverlag|location=Vienna|year=2007|edition=2007/2008|volume=1|pages=1768–71|isbn= 978-3-85200-181-4|language=German}} 9. ^{{cite journal | pmid = 21914581| year = 2011| author1 = Ueda| first1 = T| title = Kimura's disease treated with suplatast tosilate and loratadine| journal = European Journal of Dermatology : EJD| volume = 21| issue = 6| pages = 1020–1| last2 = Arai| first2 = S| last3 = Amoh| first3 = Y| last4 = Katsuoka| first4 = K| doi = 10.1684/ejd.2011.1539}} 10. ^{{cite book|title=Austria-Codex|editor=Jasek, W|publisher=Österreichischer Apothekerverlag|location=Vienna|year=2007|edition=2007/2008|volume=1|pages=1731–34|isbn= 978-3-85200-181-4|language=German}} 11. ^1 2 {{cite book|last=Mutschler|first=Ernst|author2=Gerd Geisslinger |author3=Heyo K. Kroemer |author4=Monika Schäfer-Korting |title=Arzneimittelwirkungen|publisher=Wissenschaftliche Verlagsgesellschaft|location=Stuttgart|year=2001|edition=8|pages=456–461|isbn=978-3-8047-1763-3|language=German}} 12. ^{{cite journal | title=Transfer of drugs and other chemicals into human milk | journal=Pediatrics | volume=108 | issue=3 | pages=776–89 | date=1 September 2001 | url=http://aappolicy.aappublications.org/cgi/content/full/pediatrics;108/3/776 | pmid=11533352 | author=Committee on Drugs | deadurl=no | archiveurl=https://web.archive.org/web/20071023053121/http://aappolicy.aappublications.org/cgi/content/full/pediatrics%3B108/3/776#T1 | archivedate=23 October 2007 | df= }} 13. ^{{cite web|url=http://www.aafp.org/afp/20031115/steps.html|title=Desloratadine for Allergic Rhinitis|publisher=American Family Physician|date=November 15, 2003|last1=See|first1=Sharon|deadurl=no|archiveurl=https://web.archive.org/web/20050724082052/http://www.aafp.org/afp/20031115/steps.html|archivedate=July 24, 2005|df=}} 14. ^{{cite web | url = http://allergies.emedtv.com/claritin/claritin-and-alcohol.html | title = Claritin and Alcohol | author = Kristi Monson, PharmD | publisher = emedtv.com | deadurl = no | archiveurl = https://web.archive.org/web/20120424203016/http://allergies.emedtv.com/claritin/claritin-and-alcohol.html | archivedate = 2012-04-24 | df = }} 15. ^{{Cite journal|last1=Kosoglou|first1=T.|last2=Salfi|first2=M.|last3=Lim|first3=J.M.|last4=Batra|first4=V.K.|last5=Cayen|first5=M.N.|last6=Affrime|first6=M.B.|title=Evaluation of the pharmacokinetics and electrocardiographic pharmacodynamics of loratadine with concomitant administration of ketoconazole or cimetidine|journal=British Journal of Clinical Pharmacology|volume=50|issue=6|pages=581–589|pmc=2015013|date=December 2000|pmid=11136297|doi=10.1046/j.1365-2125.2000.00290.x}} 16. ^1 {{cite journal|title=Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine: a comparative review|journal=Clin Pharmacokinet|volume=47|issue=4|pages=217–30|pmid=18336052|year=2008|author1=Devillier|first1=P|last2=Roche|first2=N|last3=Faisy|first3=C|doi=10.2165/00003088-200847040-00001}} 17. ^{{cite book |author=Nelson, Wendel L. |editors=Williams, David H.; Foye, William O.; Lemke, Thomas L. |title=Foye's principles of medicinal chemistry |publisher=Lippincott Williams & Wilkins |location=Hagerstown, MD |year=2002 |chapter=Antihistamines and related antiallergic and antiulcer agents |pages=805 |isbn=978-0-683-30737-5}} 18. ^{{cite journal |vauthors=Ghosal A, Gupta S, Ramanathan R, etal |title=Metabolism of loratadine and further characterization of its in vitro metabolites |journal=Drug Metab Lett |volume=3 |issue=3 |pages=162–70 |date=August 2009 |pmid=19702548 |doi=10.2174/187231209789352067}} 19. ^{{cite journal | pmid = 12169042| year = 2002| author1 = Affrime| first1 = M| title = A pharmacokinetic profile of desloratadine in healthy adults, including elderly| journal = Clinical Pharmacokinetics| volume = 41 Suppl 1| pages = 13–9| last2 = Gupta| first2 = S| last3 = Banfield| first3 = C| last4 = Cohen| first4 = A| doi=10.2165/00003088-200241001-00003}} 20. ^{{cite journal |author=Kay GG, Harris AG |title=Loratadine: a nonsedating antihistamine. Review of its effects on cognition, psychomotor performance, mood and sedation |journal=Clinical and Experimental Allergy |volume=29 Suppl 3 |issue= |pages=147–50 |date=July 1999 |pmid=10444229 |doi= 10.1046/j.1365-2222.1999.0290s3147.x}} 21. ^1 {{cite news | url=https://www.nytimes.com/2001/03/11/magazine/the-claritin-effect-prescription-for-profit.html?pagewanted=1 | work=The New York Times | title=The Claritin Effect; Prescription for Profit | first=Stephen S. | last=Hall | date=2001-03-11 | accessdate=2010-06-28 | deadurl=no | archiveurl=https://web.archive.org/web/20150527160442/http://www.nytimes.com/2001/03/11/magazine/the-claritin-effect-prescription-for-profit.html?pagewanted=1 | archivedate=2015-05-27 | df= }} 22. ^{{Cite web|url=http://www.prnewswire.com/news-releases/schering-plough-loses-patent-lawsuit-over-claritin-opening-door-for-cheaper-generic-versions-70880857.html|title=Schering-Plough Loses Patent Lawsuit Over Claritin, Opening Door For Cheaper Generic Versions|last=|first=|date=2003-08-05|website=PRNewswire|publisher=Leiner Health Products|access-date=2016-06-26|deadurl=no|archiveurl=https://web.archive.org/web/20160812201604/http://www.prnewswire.com/news-releases/schering-plough-loses-patent-lawsuit-over-claritin-opening-door-for-cheaper-generic-versions-70880857.html|archivedate=2016-08-12|df=}} 23. ^1 Cohen JP et al. Switching prescription drugs to over the counter. BMJ. 2005 Jan 1;330(7481):39-41. {{PMID|15626806}} [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC539854/ PMC 539854] {{webarchive|url=https://web.archive.org/web/20170910174538/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC539854/ |date=2017-09-10 }} 24. ^Association of the European Self-Medication Industry Database. Loratadine OTC regulation {{webarchive|url=https://web.archive.org/web/20151208062901/http://www.aesgp.eu/facts-figures/otc-ingredients/?result=name&multiselect=all&country=28&country=29&country=4&country=1&country=18&country=31&country=32&country=33&country=19&country=20&country=6&country=42&country=7&country=9&country=3&country=10&country=21&country=11&country=12&country=34&country=22&country=36&country=37&country=23&country=38&country=24&country=14&country=39&country=25&country=26&country=35&country=15&country=16&country=27&country=13&country=17&country=40&country=41&otc=230 |date=2015-12-08 }} Page accessed April 11, 2015 25. ^1 2 3 4 5 6 7 {{cite web|title=Loratadine International Brands|url=https://www.drugs.com/international/loratadine.html|publisher=Drugs.com|accessdate=19 February 2017|deadurl=no|archiveurl=https://web.archive.org/web/20160304002803/http://www.drugs.com/international/loratadine.html|archivedate=4 March 2016|df=}} 26. ^1 2 3 4 5 {{Cite news|url=https://www.statnews.com/2015/12/11/untold-story-tvs-first-prescription-drug-ad/|title=The untold story of TV’s first prescription drug ad|date=2015-12-11|work=STAT|access-date=2017-10-26|language=en-US}} 27. ^1 2 {{Cite news|url=http://www.mmm-online.com/features/dtc-the-first-10-years/article/24443/|title=DTC: The first 10 years|date=2007-04-01|work=MM&M|access-date=2017-10-26|language=en}} 28. ^{{Cite news|url=http://adage.com/article/news/ten-years-direct-consumer-drug-advertising/112215/|title=Ten Years Later: Direct to Consumer Drug Advertising|access-date=2017-10-26|language=en}} 29. ^{{Cite news|url=https://www.nytimes.com/2001/03/11/magazine/the-claritin-effect-prescription-for-profit.html|title=The Claritin Effect; Prescription for Profit|last=Hall|first=Stephen S.|date=2001-03-11|work=The New York Times|access-date=2017-10-26|language=en-US|issn=0362-4331}} External links
| title = Pharmacodynamics | titlestyle = background:#ccccff | list1 ={{Histamine receptor modulators}}{{PAF receptor modulators}}{{Xenobiotic-sensing receptor modulators}} }}{{Tricyclics}}{{portal bar|Pharmacy and pharmacology|Medicine}} 11 : H1 receptor antagonists|Carbamates|Schering-Plough|Merck|Wyeth|Piperidines|Chloroarenes|Benzocycloheptapyridines|Peripherally selective drugs|World Health Organization essential medicines|RTT |
随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识,基本涵盖了大多数领域的百科知识,是一部内容自由、开放的电子版国际百科全书。